GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD₂ and Releasing Inducible IL-18.

ABSTRACT: Chimeric antigen receptor (CAR)-engineered T cells can be highly effective in the treatment of hematological malignancies, but mostly fail in the treatment of solid tumors. Thus, approaches using 4^th advanced CAR T cells secreting immunomodulatory cytokines upon CAR signaling, known as TRUCKs ("T cells redirected for universal cytokine-mediated killing"), are currently under investigation. Based on our previous development and validation of automated and closed processing for GMP-compliant manufacturing of CAR T cells, we here present the proof of feasibility for translation of this method to TRUCKs. We generated IL-18-secreting TRUCKs targeting the tumor antigen GD₂ using the CliniMACS Prodigy^® system using a recently described "all-in-one" lentivir

SUBMITTER: Glienke W 

PROVIDER: S-EPMC8988144 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature